Yubo International Biotech Limited
YBGJ
$0.01
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -- | -- | -- | -202.38% | 4.62% |
| Gross Profit | -- | -- | -- | -76.24% | -125.66% |
| SG&A Expenses | -39.41% | -18.63% | 35.76% | -21.57% | 43.46% |
| Depreciation & Amortization | -12.10% | 0.67% | -4.09% | -63.16% | 5.31% |
| Other Operating Expenses | -69.34% | -120.94% | -50.41% | -47.14% | 494.56% |
| Total Operating Expenses | -50.07% | -58.27% | 13.18% | -34.58% | 47.15% |
| Operating Income | 50.07% | 58.27% | -14.14% | 31.76% | -9,804.69% |
| Income Before Tax | 50.06% | 58.27% | -14.11% | 31.79% | -9,958.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 50.06% | 58.27% | -14.11% | 31.79% | -9,958.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -16.92% | -72.60% | -1.55% | -- | -- |
| Net Income | 52.34% | 56.34% | -15.45% | 44.01% | -9,319.05% |
| EBIT | 50.07% | 58.27% | -14.14% | 31.76% | -9,804.69% |
| EBITDA | 53.47% | 62.95% | -16.48% | 22.79% | -1,170.47% |
| EPS Basic | 60.42% | 56.82% | 88.57% | 44.19% | -4,900.00% |
| Normalized Basic EPS | 62.07% | 56.00% | 88.24% | 51.85% | -- |
| EPS Diluted | 60.42% | 56.82% | 88.57% | 44.19% | -4,900.00% |
| Normalized Diluted EPS | 62.07% | 56.00% | 88.24% | 51.85% | -- |
| Average Basic Shares Outstanding | 23.41% | 0.00% | 900.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 23.41% | 0.00% | 900.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |